Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01196988 · ClinicalTrials.gov registry record · Phase 3
Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,027
- Enrollment target
NCT01196988 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 3,027 participants.
The verdict
NCT01196988, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,027 participants
- Enrollment target
Study Summary
This study is designed to assess the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals' investigational vaccine GSK2321138A in children aged 3 to 17 years, and to describe safety and immunogenicity of the GSK Biologicals' investigational vaccine GSK2321138A in children aged 6 to 35 months.
Interventions
- BIOLOGICAL Influenza vaccine GSK2321138A
- BIOLOGICAL FluarixTM
- BIOLOGICAL Influenza vaccine GSK2604409A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,027 participants |
| Start Date | 2010-10-04 |
| Est. Completion | 2011-06-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01196988
The ClinicalTrials.gov registry entry for NCT01196988 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,027 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Influenza vaccine GSK2321138A is the first listed.
NCT01196988 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01196988 about?
NCT01196988 is a clinical study titled "Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children". This study is designed to assess the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals' investigational vaccine GSK2321138A in children aged 3 to 17 years, and to describe safety and immunogenicity of the GSK Biologicals' investigational vaccine GSK2321138A in children aged 6 to 35 mont...
What is the current status of trial NCT01196988?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,027 participants. The study started on 2010-10-04. Estimated completion is 2011-06-15.
What interventions are being tested in trial NCT01196988?
The interventions under investigation include: Influenza vaccine GSK2321138A (BIOLOGICAL), FluarixTM (BIOLOGICAL), Influenza vaccine GSK2604409A (BIOLOGICAL).
Who is sponsoring clinical trial NCT01196988?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.